Literature DB >> 33626961

Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study.

Daniel Gallacher1, Peter Kimani1, Nigel Stallard1.   

Abstract

Previous work examined the suitability of relying on routine methods of model selection when extrapolating survival data in a health technology appraisal setting. Here we explore solutions to improve reliability of restricted mean survival time (RMST) estimates from trial data by assessing model plausibility and implementing model averaging. We compare our previous methods of selecting a model for extrapolation using the Akaike information criterion (AIC) and Bayesian information criterion (BIC). Our methods of model averaging include using equal weighting across models falling within established threshold ranges for AIC and BIC and using BIC-based weighted averages. We apply our plausibility assessment and implement model averaging to the output of our previous simulations, where 10,000 runs of 12 trial-based scenarios were examined. We demonstrate that removing implausible models from consideration reduces the mean squared error associated with the restricted mean survival time (RMST) estimate from each selection method and increases the percentage of RMST estimates that were within 10% of the RMST from the parameters of the sampling distribution. The methods of averaging were superior to selecting a single optimal extrapolation, aside from some of the exponential scenarios where BIC already selected the exponential model. The averaging methods with wide criterion-based thresholds outperformed BIC-weighted averaging in the majority of scenarios. We conclude that model averaging approaches should feature more widely in the appraisal of health technologies where extrapolation is influential and considerable uncertainty is present. Where data demonstrate complicated underlying hazard rates, funders should account for the additional uncertainty associated with these extrapolations in their decision making. Extended follow-up from trials should be encouraged and used to review prices of therapies to ensure a fair price is paid.

Entities:  

Keywords:  Monte Carlo simulation; cancer; extrapolation; health technology assessment; survival analysis

Year:  2021        PMID: 33626961     DOI: 10.1177/0272989X21992297

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  3 in total

1.  An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial.

Authors:  Mathyn Vervaart; Mark Strong; Karl P Claxton; Nicky J Welton; Torbjørn Wisløff; Eline Aas
Journal:  Med Decis Making       Date:  2021-12-30       Impact factor: 2.749

2.  Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations.

Authors:  Daniel Gallacher; Peter Kimani; Nigel Stallard
Journal:  Pharmacoeconomics       Date:  2021-09-28       Impact factor: 4.981

3.  Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.

Authors:  Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Michael J Crowther; James R Carpenter; Neil Hawkins
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 2.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.